Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Vile

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Molecular Therapy Oncolytics|March 5, 2020
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent MechanismMartin McLaughlin, Malin Pedersen, Victoria Roulstone, et al.
Cancer Research|March 26, 2002
Strategies for antigen loading of dendritic cells to enhance the antitumor immune responseScott E Strome, Stephen Voss, Ryan Wilcox, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Cancer Immunology Research|October 18, 2017
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor RecurrenceTim Kottke, Laura Evgin, Kevin G Shim, et al.
Research Square|December 4, 2023
Chimerization of the Anti-Viral CD8<sup>+</sup> T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapyRichard Vile, Mason Webb, Jacob van Vloten, et al.
Molecular Therapy Oncolytics|June 14, 2023
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic virusesMason J Webb, Timothy Kottke, Benjamin L Kendall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Molecular Therapy Oncolytics|December 10, 2016
Immunogenicity of self tumor associated proteins is enhanced through protein truncationTim Kottke, Kevin G Shim, Vanesa Alonso-Camino, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Molecular Therapy Oncolytics|March 5, 2020
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent MechanismMartin McLaughlin, Malin Pedersen, Victoria Roulstone, et al.
Cancer Research|March 26, 2002
Strategies for antigen loading of dendritic cells to enhance the antitumor immune responseScott E Strome, Stephen Voss, Ryan Wilcox, et al.
Science Advances|June 5, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activityOlivia Liseth, Elizabeth Appleton, Benjamin Kendall, et al.
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Cancer Immunology Research|October 18, 2017
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor RecurrenceTim Kottke, Laura Evgin, Kevin G Shim, et al.
Research Square|December 4, 2023
Chimerization of the Anti-Viral CD8<sup>+</sup> T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic VirotherapyRichard Vile, Mason Webb, Jacob van Vloten, et al.
Molecular Therapy Oncolytics|June 14, 2023
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic virusesMason J Webb, Timothy Kottke, Benjamin L Kendall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Molecular Therapy Oncolytics|December 10, 2016
Immunogenicity of self tumor associated proteins is enhanced through protein truncationTim Kottke, Kevin G Shim, Vanesa Alonso-Camino, et al.
Pageof 10